Next Phase Newsletter

A diversified, global, alternative asset manager has invested equally in the private and public markets. Within the private markets, the firm seeks to invest across the entire private healthcare company lifecycle, from seed to cross-over. Initial check sizes can range from $5 – 50m and will largely depend on the stage of the company. With seed stage companies, the firm can invest $1-5m. In general, the firm ascribes to the approach of doubling the size of their prior round investment in each subsequent round (from Seed -> Series A -> Series B -> Series C -> IPO), subject to milestone achievement. The firm is currently focused on USA and Western European opportunities.

The firm’s primary investment focus is disruptive therapeutics-focused companies. The firm is most interested in genetic medicines (DNA, RNA, protein-targeted therapies including gene therapy, gene editing, oligonucleotides, and small molecule approaches), precision/targeted oncology (DNA damage repair/synthetic lethality, driver/resistance mechanisms), differentiated immunotherapies (gamma-delta T-cell-targeted, bispecific T-cell engagers, new efforts at drugging difficult checkpoints/targets), CNS disorders and autoimmune disorders (new targets of interest). The firm may consider therapeutics indications outside of CNS, oncology, and autoimmune disease on a much more selective basis. In terms of stage of development, the firm is open to pre-clinical opportunities from the lead optimization phase and beyond (discovery phase will be considered too early). The firm may consider opportunities outside of therapeutics including medical devices, diagnostics, tools and digital health, but will be much more selective.

The firm has no particular company or management team requirements. The firm is willing to lead rounds but can act as a follow-on – the firm may seek board representation when acting as the lead investor. The firm seeks to hold shares of their private company investments long after their successful IPO.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A life sciences Venture Capital firm based in USA and Canada typically makes initial investments ranging from $2-6 million of equity and looks to invest $8-12 million over the lifetime of the investment. The firm expects to make 4-6 investments over the next 12 months, and prioritizes investment opportunities that are based in USA or Canada.

The firm invests primarily in Therapeutics and Medical Devices, with selective investments in diagnostic imaging and digital health. The firm generally looks for companies phase I and later that have at least some human proof-of-concept with either early human efficacy signs or very strong animal data coupled with human safety data.

The firm invests in companies throughout the United States and Canada. The firm does not look to take an active role on the management team but does look to take a board seat.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A life science venture capital firm with offices in USA and Europe typically makes equity investments into early-stage life science companies. The typical investment size ranges from €5-10 million. The third fund is looking to make 10 investments. The firm’s current fund is focused on the EU but the firm also invests in the US.

The firm is currently looking for new investment opportunities in the life science space. The firm focuses on Therapeutics and Medical Devices sectors. The firm is very opportunistic in terms of subsectors and indications, and it is most interested in companies in pre-clinical and clinical stages. In the past, the firm was active in therapeutics companies targeting drug delivery and gene therapy. The firm was also active in device companies developing single use cardiovascular devices and implantable devices.

The firm primarily invests in private companies with experienced management teams, but has the ability to also consider public companies, depending on the opportunity. The firm seeks to take a board seat in its portfolio companies.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A family office located in Canada looks to invest in clinical stage medical devices and diagnostics technologies as well as digital health companies. The firm looks to invest in companies with large market opportunities. The firm prefers to invest in Canadian companies, but will consider companies outside of Canada if they wish to expand to the Canadian market. The firm prefers to co-invest alongside other investors, and will invest $100,000-$250,000 in the initial investment, potentially contributing to additional rounds of funding.

The firm is looking for device companies, either in the medical device or diagnostic space. The firm will also consider digital health companies, focusing on mobile applications. For devices and diagnostics, the firm prefers 510k devices, but will consider PMA devices as well. These devices should be in the clinical development phase. The firm is indication agnostic, but does look for there to be a large market potential.

The firm looks for companies with strong management teams with good team dynamics, although previous entrepreneurial experience is not required.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.